908 Devices (MASS) director sells 20,000 shares under 10b5-1 plan
Christopher D. Brown, a director at 908 Devices Inc. (MASS), sold 20,000 shares of common stock at an average price of $8.84 per share. This transaction, totaling $176,800, was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. Following the sale, Brown directly holds 845,559 shares of the company's common stock.
Form 4 908 Devices Inc For: 30 June By Investing.com
This article reports on the filing of Form 4 by 908 Devices Inc. for the period ending June 30, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by an insider. The brief article itself does not provide details of the Form 4 content but indicates its publication date.
Form 4 908 Devices Inc For: 30 June By Investing.com
This article reports on a Form 4 filing for 908 Devices Inc. related to activity on June 30th. It originates from Investing.com, a financial markets news platform. The content is primarily a placeholder for the Form 4 information, surrounded by general market data and news headlines.
908 Devices (MASS) CEO sells 2,798 shares under Rule 10b5-1 plan
Kevin J. Knopp, President and CEO of 908 Devices Inc. (MASS), sold 2,798 shares of common stock at a weighted average price of $9.09 per share under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Knopp directly holds 732,825 shares, with an additional 541,223 shares held indirectly by The Kevin J. Knopp Irrevocable Trust of 2018. The sale, which totaled $25,434, was executed on June 26, 2026, as per an SEC Form 4 filing.
908 Devices CEO Kevin Knopp sells $25,433 in company stock
Kevin J. Knopp, CEO of 908 Devices Inc. (NASDAQ:MASS), sold 2,798 shares of company stock for $25,433 on June 26, 2026, at an average price of $9.09 per share. This transaction was part of a Rule 10b5-1 trading plan established in May 2025. Following the sale, Knopp directly holds 732,825 shares and indirectly controls an additional 541,223 shares through a trust.
908 Devices CEO Kevin Knopp sells $25,433 in company stock By Investing.com
Kevin J. Knopp, CEO of 908 Devices Inc., sold 2,798 shares of the company's common stock for $25,433 on June 26, 2026, as part of a Rule 10b5-1 trading plan. Despite recent stock momentum and revenue growth in Q1 2026, the company remains unprofitable with shares appearing slightly overvalued according to InvestingPro analysis. Knopp maintains significant direct and indirect holdings in the company.
908 Devices Inc.(NasdaqGM:MASS) dropped from Russell Microcap Growth Benchmark Index
908 Devices Inc. (NasdaqGM:MASS) has been removed from the Russell Microcap Growth Benchmark Index. The article also lists recent news regarding the company, including its Q1 2026 earnings call, an agreement to acquire NIRLAB Sarl for $23 million, and its Q4 2025 earnings results. The company specializes in devices for analyzing materials in various applications like forensics and bioprocessing.
908 Devices Inc. Actuals & Estimates (NASDAQ:MASS)
This article provides an overview of 908 Devices Inc. (NASDAQ: MASS) stock performance, financial actuals, and analyst estimates. It highlights key financial figures such as current price, market capitalization, earnings, and revenue, and includes analyst forecasts for future price targets. The article also covers stock volatility, employee count, and upcoming earnings report dates.
Director at 908 Devices (NASDAQ: MASS) converts 6,486 RSUs into common stock
908 Devices (NASDAQ: MASS) director Michele M. Leonhart converted 6,486 restricted stock units (RSUs) into common stock, acquiring 6,486 shares at $0.00 each as part of her equity compensation. Following this transaction, Leonhart directly holds 27,054 shares of common stock. The RSUs vest in equal annual installments over three years from June 25, 2024, contingent on continued service, with prorated vesting upon earlier service termination.
Form 4 908 Devices Inc For: 25 June By Investing.com
This article from Investing.com reports on a Form 4 filing for 908 Devices Inc. on June 25, 2026. The brief piece includes the stock symbol MASS, which experienced a -2.23% change, alongside various market data and other Investing.com articles.
908 Devices (MASS) CEO sells 60,345 shares under Rule 10b5-1 trading plan
Kevin J. Knopp, President and CEO of 908 Devices (MASS), reported selling 60,345 shares of common stock in open-market transactions over three days in June 2026. These sales, totaling approximately $550,624, were executed under a pre-scheduled Rule 10b5-1 trading plan adopted on May 20, 2025. Following these transactions, Knopp still directly holds 735,623 shares and has an indirect beneficial ownership of an additional 541,223 shares through an irrevocable trust.
908 Devices (MASS) director sells 9,900 shares under 10b5-1 plan
Christopher D. Brown, a director at 908 Devices Inc. (MASS), sold 9,900 shares of common stock at a weighted average price of $9.04 per share. This transaction was conducted under a predetermined Rule 10b5-1 trading plan adopted on November 24, 2025. Following the sale, Brown still retains a significant direct holding of 865,559 shares in the company.
908 Devices director Brown sells $89,495 in shares By Investing.com
Christopher D. Brown, a director at 908 Devices Inc. (NASDAQ:MASS), sold 9,900 shares of common stock on June 23, 2026, totaling $89,495. This sale was conducted under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week high, following a significant 65% surge in six months, and is considered overvalued according to InvestingPro analysis. After the transaction, Mr. Brown still holds a substantial number of shares, while the company recently reported increased Q1 2026 revenue but missed EPS expectations.
AWM Investment (MASS) funds log small open-market sales but keep large stake
AWM Investment Company, Inc., a major owner of 908 Devices Inc. (MASS), reported open-market sales of 7,718 shares of the company's common stock on June 22 and 23 at around $9 per share. Despite these sales, AWM-advised funds still indirectly hold a substantial stake of 4,879,773 shares, indicating the transactions were minor relative to their overall position. The sales were noted as straightforward and not related to option exercises or tax events.
Form 144 908 Devices Inc For: 23 June
This article announces a Form 144 filing for 908 Devices Inc. on June 23. It also includes standard disclaimers about the high risks involved in trading financial instruments and cryptocurrencies, emphasizing that data on Investing.com is not always real-time or accurate. The content advises investors to seek professional advice and be aware of the risks before trading.
Form 144 908 Devices Inc For: 23 June By Investing.com
This article from Investing.com simply announces a Form 144 filing by 908 Devices Inc. for June 23rd. The content is brief and primarily serves as a notification regarding this financial regulatory filing. This signals an insider's intent to sell restricted stock.
908 Devices (Nasdaq:MASS) - Stock Analysis
908 Devices Inc. (Nasdaq:MASS) provides handheld mass spectrometry devices for health and safety applications, with a market cap of US$334.7m. The company is currently unprofitable but analysts project 19.06% annual revenue growth and have recently increased price targets to US$11.00. Key developments include raising 2026 revenue guidance, strategic acquisitions, and new product enhancements like the VipIR analyzer, despite recent insider selling and past share price volatility.
908 Devices Inc. (MASS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of 908 Devices Inc. (MASS), highlighting its current valuation score of 9.25 and its position within the Healthcare Equipment & Supplies industry. The report details the company's current P/E ratio of -8.61, noting it is significantly below its recent high and above its recent low. It also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
908 Devices (MASS) TD Cowen 46th Annual Health Care Conference Summary
This summary details 908 Devices' performance and strategy from the TD Cowen 46th Annual Health Care Conference. The company achieved 18% year-over-year revenue growth and positive adjusted EBITDA in Q4 after divesting its desktop business, now focusing on handheld chemical detection. Growth is driven by illicit drug detection, industrial chemical monitoring, and defense applications, supported by innovative products like VipIR and XplorIR, with a next-gen MX908 platform expected in 2027.
908 Devices Inc. (MASS) Earnings Forecast: Future EPS & Revenue Growth Estimates
908 Devices Inc. (MASS) currently has an earnings forecast score of 9.50, ranking 1st in the Healthcare Equipment & Supplies industry. Analysts have given the company a "Strong Buy" rating with an average price target of $10.00. The expected revenue for the next quarter is $15.42 million, and the EPS is projected at -$0.18.
908 Devices Inc. (MASS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a detailed revenue breakdown for 908 Devices Inc. (MASS), categorizing its revenue by business segments and geographical regions. For the specified period, device sales revenue constituted the largest portion at 65.23%, followed by recurring revenue at 34.56%. Geographically, the United States accounted for the majority of revenue at 73.40%.
Director Mark Spoto granted options and RSUs at 908 Devices (MASS)
Mark Spoto, a director at 908 Devices (MASS), recently received significant equity compensation. He was granted 6,209 stock options with an exercise price of $8.22 and 13,656 Restricted Stock Units (RSUs) which will vest in 2027. Additionally, 14,083 existing RSUs vested and converted into common stock, increasing his direct holdings to 89,346 shares, with another 3,599 shares held indirectly.
908 Devices (NASDAQ: MASS) director receives new options, RSUs and adds shares
E. Kevin Hrusovsky, a director at 908 Devices (NASDAQ: MASS), was granted 6,209 stock options at an exercise price of $8.22 and 13,656 Restricted Stock Units (RSUs) on June 11, 2026. Additionally, 14,083 RSUs vested and converted into common stock on June 10, 2026, increasing his direct holdings to 165,390 shares, with an additional 329,675 shares held indirectly through a trust. These transactions are part of his compensation and are detailed in a Form 4 SEC filing.
[Form 4] 908 Devices Inc. Insider Trading Activity
This article details insider trading activity at 908 Devices Inc. (MASS), specifically focusing on director Keith Crandell's equity compensation. It reports his receipt of a stock option grant for 6,209 shares and 13,656 Restricted Stock Units (RSUs), and the vesting of 14,083 RSUs which converted to common stock. The report also outlines his direct and indirect shareholdings and provides a detailed SEC Form 4 filing.
908 Devices (MASS) director Brandi C. Vann granted stock options and RSUs
908 Devices Inc. director Brandi C. Vann was granted new equity awards, including stock options for 6,209 shares with an exercise price of $8.22, vesting over 12 months, and 13,656 Restricted Stock Units (RSUs). The RSUs are contingent on continued service and will fully vest on June 11, 2027, or prior to the 2027 Annual Meeting. These awards are compensation-related and do not involve open-market purchases or sales.
908 Devices (NASDAQ: MASS) investors approve directors, say-on-pay and PwC in 2026 vote
908 Devices Inc. (NASDAQ: MASS) held its 2026 Annual Meeting where shareholders approved the election of three Class III directors, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and endorsed the compensation for named executive officers. Shareholders also voted in favor of holding future "say-on-pay" votes annually. These decisions were made with a significant quorum of 76.52% of outstanding shares represented.
908 Devices (MASS) director receives options, RSUs and converts vested units
908 Devices Inc. director Anthony Hunt received equity compensation including 6,209 stock options with an exercise price of $8.22 and 13,656 Restricted Stock Units (RSUs). Additionally, 14,083 previously granted RSUs vested and converted into common stock, increasing his direct holdings to 44,168 shares. These transactions are detailed in a recent Form 4 SEC filing and outline the vesting schedules for the new awards.
908 Devices Inc. (MASS) Presents at 16th Annual East Coast IDEAS Conference - Slideshow
908 Devices Inc. (MASS) presented a slide deck at the 16th Annual East Coast IDEAS Conference. The presentation was published by 908 Devices Inc. in conjunction with the event. SA Transcripts, Seeking Alpha's transcripts team, is responsible for this content.
908 Devices (MASS) 16th Annual East Coast IDEAS Conference Summary
908 Devices presented at the 16th Annual East Coast IDEAS Conference, highlighting a strategic transformation to focus solely on handheld chemical detection for public health, safety, and defense markets. The company reported strong financial performance with 18% YoY revenue growth in 2025 and 14% in Q1 2026, alongside a diversified customer base and the acquisition of NIRLAB AG to enhance its product portfolio with AI-driven, subscription-based devices. They are addressing global threats like the opioid crisis and increasing defense needs with devices deployed in over 70 countries.
908 Devices (MASS) director logs small 100-share sale under 10b5-1 plan
Christopher D. Brown, a director at 908 Devices Inc. (MASS), reported an open-market sale of 100 shares of common stock at $9.00 per share on June 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on November 24, 2025. Following the sale, Brown directly holds 875,459 shares of the company's common stock.
908 devices director Christopher Brown sells $900 in stock
Christopher D. Brown, a director at 908 Devices Inc. (NASDAQ:MASS), sold 100 shares of company stock for $9.00 per share, totaling $900, on June 4, 2026. This transaction was part of a Rule 10b5-1 trading plan adapted in November 2025, leaving him with 875,459 shares. The company recently reported 14% revenue growth in Q1 2026 but missed EPS expectations, although it holds more cash than debt.
ARK and Cathie Wood report 1.88M shares in 908 Devices (MASS)
ARK Investment Management LLC and Catherine D. Wood have reported beneficial ownership of 1,883,206 shares of 908 Devices Inc. (MASS), representing 4.94% of the common stock. This disclosure was made via a Schedule 13G/A filing, indicating a passive investment below the 5% threshold. Both ARK and Catherine D. Wood hold specific voting and dispositive powers over these shares, as detailed in the SEC filing.
Earnings call transcript: 908 Devices Q1 2026 sees revenue growth, EPS miss
908 Devices Inc. reported Q1 2026 earnings with a 14% year-over-year revenue increase to $13.4 million, but missed EPS forecasts significantly at -$0.32 against an expected -$0.15. Despite the EPS miss, the stock rose 7.05% pre-market, driven by strong revenue performance and strategic acquisitions like RedWave and the newly announced NIRLAB. The company aims to expand its handheld detection solutions globally, enhance recurring revenue streams, and improve profitability, guiding for 19-25% revenue growth for full year 2026.
AWM Investment Co. funds trim 908 Devices (MASS) stake with 42K-share sale
AWM Investment Company, an investment adviser to several funds, has reported the sale of 42,282 shares of 908 Devices Inc. (MASS) common stock in two open-market transactions. These sales, totaling approximately $379,231, occurred on June 2 and June 4, 2026. Following these transactions, the funds advised by AWM Investment Company indirectly hold 4,887,491 shares of 908 Devices Inc.
Director at 908 Devices (NASDAQ: MASS) sells 20,000 shares under 10b5-1 plan
Christopher D. Brown, a director at 908 Devices (NASDAQ: MASS), sold 20,000 shares of common stock at a weighted average price of $8.73 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. Following the sale, Brown directly holds 875,559 shares in the company.
MASS (NASDAQ: MASS) director sells 70,000 shares via 10b5-1 notices
A director of 908 Devices Inc. (NASDAQ: MASS), Christopher Brown, has filed a Form 144 to sell 70,000 shares of common stock through multiple 10b5-1 predetermined sales. These sales include 30,000 shares on May 28, 2026, for $270,000, and 20,000 shares on May 6, 2026, for $144,668, along with additional sales in April 2026. The filing is a routine regulatory notice for selling restricted or control stock, indicating a neutral impact and sentiment.
908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
908 Devices Inc. announced that its Compensation Committee granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of common stock. These inducement grants, made on June 1, 2026, are in accordance with Nasdaq Listing Rule 5635(c)(4) and vest over four years, subject to continued employment. The exercise price for these options is $8.63 per share.
908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference
908 Devices Inc. (Nasdaq: MASS) announced that its CEO, Kevin J. Knopp, and CFO, Joe Griffith, will present and host investor meetings at the 16th Annual East Coast IDEAS Conference on June 10, 2026. The presentation will be webcast and will highlight the company's portable chemical analysis tools used in vital health, safety, and defense technology applications.
908 Devices director Christopher D. Brown sells $270,000 in stock By Investing.com
Christopher D. Brown, a director at 908 Devices Inc. (NASDAQ:MASS), sold 30,000 shares of the company's common stock for $270,000 on May 28, 2026, at $9.00 per share. This sale, executed under a Rule 10b5-1 trading plan, occurred while the stock was near its 52-week high and had seen significant year-to-date and year-over-year gains. Despite strong revenue growth in Q1 2026, the company reported an EPS miss, and InvestingPro indicates the stock is currently overvalued.
908 Devices CFO Joseph H. Griffith IV sells $62,668 in stock
Joseph H. Griffith IV, CFO of 908 Devices Inc., sold 6,940 shares of the company's stock for $62,668 on May 28, 2026. This transaction was part of a Rule 10b5-1 trading plan and occurred amidst significant stock momentum, though the stock is now retracing. Despite the stock's performance, InvestingPro analysis indicates it is overvalued and the company remains unprofitable, although it maintains a strong balance sheet.
908 Devices director Christopher D. Brown sells $270,000 in stock
Christopher D. Brown, a director at 908 Devices Inc. (NASDAQ:MASS), sold 30,000 shares of company stock for $270,000 on May 28, 2026, at $9.00 per share, near its 52-week high. The sale was executed under a Rule 10b5-1 trading plan adopted in November 2025. This transaction follows the company's Q1 2026 earnings report, which showed a 14% revenue increase but an EPS miss of -$0.32 against an anticipated -$0.15.
908 Devices CFO Joseph H. Griffith IV sells $62,668 in stock
Joseph H. Griffith IV, CFO of 908 Devices Inc. (NASDAQ:MASS), sold 6,940 shares of common stock for $62,668 at $9.03 per share on May 28, 2026, following a Rule 10b5-1 trading plan adopted in June 2025. This sale occurred despite the stock's strong year-to-date performance. The company also recently reported a 14% revenue increase in Q1 2026, though EPS missed forecasts.
908 Devices (MASS) CFO sells 6,940 shares in Rule 10b5-1 trade
908 Devices Inc. CFO Joseph H. Griffith IV sold 6,940 shares of common stock at $9.03 per share on May 28, 2026, through a pre-arranged Rule 10b5-1 trading plan. Following this transaction, he still directly holds 132,956 shares. The sale amounted to $62,668 and was reported in a Form 4 filing, indicating it was a planned disposal rather than a discretionary one.
908 Devices (NASDAQ: MASS) director sells 30K shares under 10b5-1 plan
908 Devices Inc. director Christopher D. Brown sold 30,000 shares of common stock at $9.00 per share in an open-market transaction on May 28, 2026. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. Following the transaction, Brown directly holds 895,559 shares of the company’s stock.
AWM Investment trims 908 Devices (MASS) stake with 186,942-share sale
AWM Investment Company, Inc., a 10% owner of 908 Devices Inc. (MASS), has reported open-market sales of 186,942 shares of common stock through a limited partnership on May 27–28, 2026. The sales were executed at prices ranging from approximately $8.25 to $8.66 per share, totaling over $1.6 million. Following these transactions, AWM Investment Company indirectly holds 4,929,773 shares of 908 Devices Inc.
Awm investment sells $1.61m of 908 Devices stock By Investing.com
AWM Investment Company, Inc. sold approximately $1.61 million worth of 908 Devices Inc. (NASDAQ:MASS) stock across May 27 and May 28, 2026, disposing of 186,942 shares at prices between $8.25 and $8.6594. Despite recent stock surges, the company recently reported mixed Q1 2026 results with 14% revenue growth but an EPS miss of -113.33%. Following these transactions, AWM Investment Company indirectly holds 4,929,773 shares.
[144] 908 Devices Inc. SEC Filing
This article announces an SEC Form 144 filing by 908 Devices Inc., detailing a proposed sale of securities. The filing indicates that 6,940 shares of common stock, acquired as Restricted Stock Units on February 1, 2025, with an aggregate market value of $56,630.40, are to be sold through Morgan Stanley Smith Barney LLC. The document originates from the United States Securities and Exchange Commission and outlines the required information for the sale under Rule 144.
908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference
908 Devices Inc. announced that CEO Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 16th Annual East Coast IDEAS Conference on June 10, 2026. The company will discuss its purpose-built handheld chemical analysis tools used in vital health, safety, and defense tech applications. The presentation will be webcast and accessible via the conference and company websites.
908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference
908 Devices Inc. (Nasdaq: MASS) announced that CEO Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 16th Annual East Coast IDEAS Conference on June 10, 2026, at 8:35 a.m. Eastern Time. The presentation will be webcast. The company specializes in handheld chemical analysis tools for health, safety, and defense applications.
908 Devices Inc. (MASS) Stock Price | Live Quotes & Charts | NASDAQ
908 Devices Inc. (MASS) saw its stock price increase after strong Q1 results, a raised 2026 revenue outlook, and an acquisition. The stock's current performance shows a range between $8.08 and $9.34, with support at $7.50. Investors are looking forward to the annual meeting on June 11 for updates on the NIRLAB integration and 2026 demand trends.
